Join Annexon for a virtual investor event providing an overview of Annexon’s platform of targeted immunotherapies including vonaprument, a neuroprotective C1q inhibitor with potential to be the first targeted vision-preserving therapy for GA. Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.

The event will feature Roger Goldberg, MD, MBA (Bay Area Retina Associates and ARCHER II Clinical Investigator), who will join company management to discuss the unmet need and current treatment landscape for geographic atrophy (GA), the advanced form of dry, age-related macular degeneration (AMD) of the retina.

A live question and answer session will follow the formal presentations.